公开(公告)号：US20200255372A1

公开(公告)日：2020-08-13

申请号：US16578047

申请日：2019-09-20

Applicant: Millendo Therapeutics, Inc.

Inventor： Stephen Warren Hunt, III ,  Martin Douglas Phillips ,  Robert Matunas ,  Herman Chen ,  Aimesther Betancourt ,  Charles Uzarama ,  Roch Thibert

IPC: C07C275/28 ,  C07C273/18 ,  A61K31/17 ,  A61K9/20 ,  A61K9/50

Abstract: A novel solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N′-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride (also referred to “ATR-101”) suitable for oral dosing, and to compositions, methods and kits relating thereto. ATR-101 has particular utility in the treatment of, for example, aberrant adrenocortical cellular activity, including adrenocortical carcinoma (ACC), congenital adrenal hyperplasia (CAH) and Cushing's syndrome.

公开(公告)号：US10059660B2

公开(公告)日：2018-08-28

申请号：US15370980

申请日：2016-12-06

Applicant: Millendo Therapeutics, Inc.

Inventor： Stephen Warren Hunt, III ,  Martin Douglas Phillips ,  Robert Matunas ,  Herman Chen ,  Aimesther Betancourt ,  Charles Uzarama ,  Roch Thibert

IPC: A61K9/50 ,  C07C275/28 ,  C07C273/18 ,  A61K9/20 ,  A61K31/17

CPC classification number: C07C275/28 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/2081 ,  A61K9/5084 ,  A61K31/17 ,  C07C273/1809 ,  C07C2601/08

Abstract: A novel solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N′-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride (also referred to “ATR-101”) suitable for oral dosing, and to compositions, methods and kits relating thereto. ATR-101 has particular utility in the treatment of, for example, aberrant adrenocortical cellular activity, including adrenocortical carcinoma (ACC), congenital adrenal hyperplasia (CAH) and Cushing's syndrome.

公开(公告)号：US20170305843A1

公开(公告)日：2017-10-26

申请号：US15370980

申请日：2016-12-06

Applicant: Millendo Therapeutics, Inc.

Inventor： Stephen Warren Hunt, III ,  Martin Douglas Phillips ,  Robert Matunas ,  Herman Chen ,  Aimesther Betancourt ,  Charles Uzarama ,  Roch Thibert

IPC: C07C275/28 ,  A61K31/17 ,  A61K9/50 ,  A61K9/20 ,  C07C273/18 ,  C07C2601/08

CPC classification number: C07C275/28 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/2081 ,  A61K9/5084 ,  A61K31/17 ,  C07C273/1809 ,  C07C2601/08

Abstract: A novel solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N′-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride (also referred to “ATR-101”) suitable for oral dosing, and to compositions, methods and kits relating thereto. ATR-101 has particular utility in the treatment of, for example, aberrant adrenocortical cellular activity, including adrenocortical carcinoma (ACC), congenital adrenal hyperplasia (CAH) and Cushing's syndrome.